Research progress on ocular adverse reactions related to paclitaxels and their prevention and treatment
10.3760/cma.j.cn114015-20200901-00922
- VernacularTitle:紫杉醇类药物眼部不良反应及其防治研究进展
- Author:
Yating YE
1
;
Guorui DOU
;
Tianfang CHANG
;
Zhaojie CHU
Author Information
1. 西北大学生命科学学院中药学专业，西安 710032
- Publication Type:Journal Article
- Keywords:
Taxoids;
Eye diseases;
Drug-related side effects and adverse reactions
- From:
Adverse Drug Reactions Journal
2021;23(6):312-316
- CountryChina
- Language:Chinese
-
Abstract:
The ocular adverse reactions of paclitaxels can involve the ocular surface, ocular appendages and intraocular tissue, with various clinical manifestations, such as dry eye, lacrimal duct obstruction, conjunctivitis, keratitis, macular edema, retinal injury, optic nerve injury, etc., which can lead to irreversible visual impairment. The mechanism of ocular adverse reactions is still unclear. In these adverse reactions, macular edema may be related to the dysfunction of retinal pigment epithelial cells and Müller cells caused by paclitaxel, and others may be related to the cytotoxicity of paclitaxels. Baseline eye examination should be performed prior to the use of paclitaxels, and new ocular symptoms should be closely monitored during the treatment. Ocular adverse reactions can be diagnosed definitively through routine ophthalmic examination. The main treatments are timely adjustment of drugs and symptomatic treatments.
